PRTODAY / NewswireToday Free press release distribution service network

More news: Software
Written by / Agency / Source: Kenexa | IBM

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

IBM and Quest Diagnostics Launch Watson-Powered Genomic Sequencing Service to Help Physicians Bring Precision Cancer Treatments to Patients Nationwide - Memorial Sloan Kettering Cancer Center to Provide Deep Knowledge Base to Augment Watson’s Data Sources and Quest’s Medical Reporting New Service Extends Reach to Community Oncologists Who Provide 70 Percent of Cancer Care [NYSE: DGX] - QuestDiagnostics.co
IBM and Quest Diagnostics Launch Watson-Powered Genomic Sequencing Service to Help Physicians Bring Precision Cancer Treatments to Patients Nationwide

 

NewswireToday - /newswire/ - Cambridge, MA, United States, 2016/10/18 - Memorial Sloan Kettering Cancer Center to Provide Deep Knowledge Base to Augment Watson’s Data Sources and Quest’s Medical Reporting New Service Extends Reach to Community Oncologists Who Provide 70 Percent of Cancer Care [NYSE: DGX] - QuestDiagnostics.co. NASDAQ: KNXA

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Software Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

IBM Watson Health and Quest Diagnostics today announced the launch of IBM Watson Genomics from Quest Diagnostics, a new service that helps advance precision medicine by combining cognitive computing with genomic tumor sequencing. Memorial Sloan Kettering Cancer Center (MSK) will supplement Watson’s corpus of scientific data with OncoKB, a precision oncology knowledge base to help inform precision treatment options for cancer patients.

The launch marks the first time that Watson for Genomics has been made widely available to patients and physicians across the country. Quest Diagnostics, a leader in genomic sequencing and oncology diagnostics that serves half the nation’s physicians and hospitals, extends these advanced capabilities to thousands of the country’s community oncologists, who provide an estimated 70 percent of cancer care in the United States. The Broad Institute of MIT and Harvard will provide additional genome sequencing capabilities as part of the collaboration.

The new service involves laboratory sequencing and analysis of a tumor’s genomic makeup to help reveal mutations that can be associated with targeted therapies and clinical trials. Watson then compares those mutations against relevant medical literature, clinical studies, pharmacopeia and carefully annotated rules created by leading oncologists, including those from MSK. Watson for Genomics ingests approximately 10,000 scientific articles and 100 new clinical trials every month.

“The beauty of Watson is that it can be used to dramatically scale access to knowledge and scientific insight, whether a patient is being treated in an urban academic medical center or a rural community clinic,” said John Kelly III, PhD, senior vice president, IBM Research and Cognitive Solutions. “Through this collaboration with the cancer community’s leading clinical and pathology experts, thousands of more patients can potentially benefit from the world’s growing body of knowledge about this disease.”

Bolstering the corpus of data Watson uses, MSK will provide OncoKB, a database of clinical evidence that will help Watson uncover treatment options that could target the specific genetic abnormalities that are causing the growth of the cancer. Comparison of literature that may take medical experts weeks to prepare can now be completed in significantly less time.

“Precision medicine is changing the way we treat cancer and giving new hope to people living with the disease,” said Jay G. Wohlgemuth, M.D., chief medical officer and senior vice president of research, development and medical, Quest Diagnostics. “However, access to genomic sequencing and tumor analysis required to determine appropriate precision medicine treatments for a patient can be a challenge. This service combines Quest’s state-of-the-art tumor analysis and national access with the cognitive computing of IBM’s Watson and the deep cancer treatment expertise of MSK. This is a powerful combination that we believe it will leap frog conventional genomic services as a better approach for identifying targeted oncology treatments.”

How the Solution Works
The efficacy of cancer therapy often depends on the type of gene mutations occurring in the cancer tumor. Many of the latest therapies are designed to work by targeting tumors with a specific genetic makeup. A therapy that is effective for one type of cancer may in fact be efficacious for many others that share similar mutations. But these mutations vary for each individual and can even change during treatment. Correlating them to the appropriate treatments requires genomic sequencing expertise as well as information from knowledge bases, which must be routinely updated to account for rapidly evolving scientific discoveries, available drug therapies and, for patients for whom no therapy is indicated, and appropriate clinical trials.

The new service helps close these gaps: To access Watson’s evidence-based report, the treating oncologist or other physician will send a patient’s solid tumor biopsy tissue to Quest Diagnostics, where pathologists will prepare the tissue sample for genomic sequencing. Scientists at Quest will then sequence the treatment-associated genes using advanced next-generation sequencing technologies and feed the genetic file into Watson. Watson will then use the sequenced genetic data and compare those data against massive bodies of clinical, scientific and pharmacological databases to help uncover potential therapeutic options that match the patient’s tumor mutations. A Quest pathologist will review and validate the results and prepare a report to send back to the treating physician.

“We now know that genetic alterations are responsible for many cancers, but it remains challenging for most clinicians to deliver on the promise of precision medicine since it requires specialized expertise and a time-consuming interpretation of massive amounts of data,” said Paul Sabbatini, MD, Deputy Physician-in-Chief for Clinical Research, Memorial Sloan Kettering Cancer Center. “Through this collaboration, oncologists will have access to MSK’s expertly curated information about the effects and treatment implications of specific cancer gene alterations. This has the power to scale expertise and help improve patient care.”

About IBM Watson Health
Watson (ibm.com/watson | ibm.com/watsonhealth) is the first commercially available cognitive computing capability representing a new era in computing. The system, delivered through the cloud, analyzes high volumes of data, understands complex questions posed in natural language, and proposes evidence-based answers. Watson continuously learns, gaining in value and knowledge over time, from previous interactions. In April 2015, the company launched IBM Watson Health and the Watson Health Cloud platform. The new unit will help improve the ability of doctors, researchers and insurers to innovate by surfacing insights from the massive amount of personal health data being created and shared daily. The Watson Health Cloud allows this information to be de-identified, shared and combined with a dynamic and constantly growing aggregated view of clinical, research and social health data.

About Quest Diagnostics
Quest Diagnostics (QuestDiagnostics.com) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 44,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

About Memorial Sloan Kettering
Memorial Sloan Kettering (mskcc.org) is the world’s oldest and largest private cancer center, home to more than 14,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. As an independent institution, MSK combines 130 years of research and clinical leadership with the freedom to provide highly individualized, exceptional care to each patient. And MSK’s always-evolving educational programs continue to train new leaders in the field, here and around the world.

Contacts
Kim Gorode - Quest Diagnostics Media Relations
P: +1 973-520-2800 - E: kimberly.b.gorode[.]questdiagnostics.com.

Nicole McNamara - Memorial Sloan Kettering Media Relations
P: +1 646-227-3633 - E: mcnamarn[.]mskcc.org.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Software Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Kenexa | IBM

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
Software Warnings - IMPORTANT:
Always be aware/cautious about what you download on your computer/mobile! PURCHASE SOFTWARE related keywords / Banner Ads. Click HERE for details!
.

 
  Your Banner Ad showing on ALL
Software articles,
CATCH Visitors via Your Competitors Announcements!


IBM and Quest Diagnostics Launch Watson-Powered Genomic Sequencing Service to Help Physicians Bring Precision Cancer Treatments to Patients Nationwide

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Christine Douglass - IBM.com 
415-535-4479 cgdouglass[.]us.ibm.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Kenexa | IBM securities in any jurisdiction including any other companies listed or named in this release.

Software via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Kenexa | IBM / Company Profile


Read Software Most Recent Related Newswires:

Permanent TSB to Improve Contact Centre Performance and Compliance with Noble Systems Composer Real-Time Speech Analytics
Rush Health Selects InterSystems HealthShare to Integrate Health Records, Support Value-Based Care
CommutAir Leverages The Weather Company, an IBM Business, to Harness the Power of Big Data from the Tarmac
Leading Independent Research Firm Cites TIBCO as a Strong Performer in Insight Platform Report
Saba Named a Leader in Learning and Performance Management
Infor Recognized as Top Retail Software Provider in 2016 RIS News LeaderBoard
IBM Debuts Blockchain Ecosystem to Help Accelerate Growth of Networks on Hyperledger Fabric
IBM Launches New Bluemix Services with GitHub and Slack Integration to Speed App Development in the Cloud
Yellowfin Launches Analytics Industry’s First Virtualized Integrated Data Preparation Module
TIBCO Releases TIBCO Mashery Local API Management Solution for Hybrid Gateway Deployments
Comways and Altitude Highlight Flexible Solutions at Belgium Contact Center Congress
Gruppo Campari Chooses OpenText Business Network for B2B Growth
Infor Delivers Enhanced Mobile Equipment Solution
Mentor Graphics and SiliconIndia Announce 2016 Leadership Awards for the Embedded/VLSI Industry
Korean Retailer Homeplus Optimizes Store Planning with JDA Category Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)